Doer Biologic News Today

Fast, Ad-Free News Updates

Stay updated with breaking news from Doer Biologic. Real-time updates on events, politics, business and more.

Zhejiang Doer Biologics Announces Clinical Trial Collaboration with MSD to Evaluate DR30303 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Gastric or Gastroesophageal Junction Cancer

December 16, 2022

/PRNewswire/ -- Hangzhou, Zhejiang, China, [December 9th, 2022], Zhejiang Doer Biologics Co., Ltd. ("Doer Bio"), a clinical stage biopharmaceutical company...

United States Yanshan Huang Yongliang Fang Merck Co Inc Merck Sharp Dohme Zhejiang Doer Biologics Co Ltd

Source: prnewswire.com

Licensing Agreement to Drive Multi-specific Biotherapeutics Development

January 17, 2022

Zhejiang Doer Biologics Co, Ltd and Lonza have entered into a research license agreement for Doer Biologics to use Lonza&rsquo;s XS Technologies&reg;&nbsp;offering for production of its proprietary MultipleBody&reg;&nbsp;and SMART-VHHBody platform technology. Click to read more...

Yanshan Huang Peter Droc Drug Product Services Zhejiang Doer Biologics Co Ltd Doer Biologics Doer Biologic

Source: labmate-online.com

Explore More Categories

World News India News Business Technology Sports Entertainment Health Science

Navigation

Doer Biologic News Today

Zhejiang Doer Biologics Announces Clinical Trial Collaboration with MSD to Evaluate DR30303 in Combination with KEYTRUDA&#xAE; (pembrolizumab) in Patients with Gastric or Gastroesophageal Junction Cancer

Licensing Agreement to Drive Multi-specific Biotherapeutics Development

Explore More Categories

Zhejiang Doer Biologics Announces Clinical Trial Collaboration with MSD to Evaluate DR30303 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Gastric or Gastroesophageal Junction Cancer